Skip to main content

Table 1 Clinical characteristics of AML patients according to FLT3/ITD status

From: Immunoprofiling of leukemic stem cells CD34+/CD38−/CD123+ delineate FLT3/ITD-positive clones

Patient characteristics AML pos for FLT3/ITD AML neg for FLT3/ITD
No. of patients 12 27
Male/female 8/4 17/10
Age at diagnosis, median, (range) 62 (23–73) 69 (23–88)
WBC count at diagnosis × 109/L, median (range) 6.6 (0.9–179) 6.3 (0.7–227)
BM blasts % by morphology, median (range) 72 (26–85) 35 (20–87)
AML de novo/secondary n (%) 9 (75)/3 (25) 23 (85)/4 (15)
FAB classification, n (%)
 Mo 0 (0) 0 (0)
 M1 6 (50) 2 (7)
 M2 1 (8) 10 (37)
 M3 2 (17) 2 (7)
 M4 1 (8) 3 (11)
 M5 1 (8) 4 (15)
 M6 0 (0) 0 (0)
 M7 0 (0) 0 (0)
 Not classified 1 (8) 6 (22)
Cytogenetic risk group, n (%)
Favorable 2 (17) 4 (15)
 Intermediate 10 (83) 13 (48)
 Poor 0 (0) 9 (33)
 Insufficient sample 0 (0) 1 (4)
Induction therapy response, n (%)
 CR 7 (70) 15 (88)
 Failure 3 (30) 2 (12)